Researchers See More Ischemic Events With Glyburide Than Gliclazide.

HeartWire  (10/4, Wood) reports, "An observational study focused on the cardiotoxic effects of sulfonylurea drugs has found that the risk of ischemic events may be higher with a specific subclass of these agents than with others." Investigators "reviewed administrative health records for the province of Alberta, Canada, identifying more than 11 000 diabetic patients using either gliclazide or glyburide who also had a history of ischemic heart disease." The researchers found that "rates of ACS-related hospitalization or death were higher among patients taking glyburide than those taking gliclazide." The findings were presented at the European Association for the Study of Diabetes 2012 Meeting.